๐ COVID-19: The Uninvited Guest in the Intensive Care Unit (ICU) Implications for Pharmacotherapy.
As the number of cases of COVID-19 (SARS-CoV-2) rise in the United States (US), the number of severe cases (those requiring ICU admission) rise with it. Initially, the estimate for severe cases was approximated at 5% based on experience from China.(1, 2) However, the World Health Organization's (WHO) estimate from China for severe and critical cases is near 20% (Table).(3) The primary clinical feature of COVID-19 is pneumonia, the severity of which directs the clinical course; it has been estimated that, of patients admitted to the ICU, up to half may require either invasive or non-invasive ventilatory support.(4) This has created an unprecedented situation for emergency and critical care medicine.
keywords
๐ COVID-19 (1240)
๐ Corona virus (74)
๐ Intensive Care Unit (2)
๐ acute respiratory distress syndrome (ARDS) (47)
author
๐ค Stringer, Kathleen A
๐ค Puskarich, Michael A
๐ค Kenes, Michael T
๐ค Dickson, Robert P
year
โฐ 2020
journal
๐ Pharmacotherapy
issn
๐
volume
number
page
citedbycount
0
download
๐ [BibTeX]